Breakthrough in Clinical Treatment of Chronic Drug-Induced Liver Injury: Optimizing Steroid Regimen and Indications – A Voice from AASLD China

Breakthrough in Clinical Treatment of Chronic Drug-Induced Liver Injury: Optimizing Steroid Regimen and Indications – A Voice from AASLD China

2023.12.21
Recently, the Liver Disease Department and Pathology Department at the Fifth Medical Center of the People's Liberation Army General Hospital (formerly the PLA Third O2 Hospital) collaborated to achieve a new breakthrough in the clinical treatment of Chronic Drug-Induced Liver Injury (DILI). The research teams, led by Dr. Zhengsheng Zou, Jingmin Zhao, and Dong Ji, previously pioneered the establishment of a 48-week Steroid Stepwise Reduction (48w-SSR) treatment plan for chronic recurrent DILI, demonstrating its efficacy and safety through rigorous Randomized Controlled Trials (RCTs). The results were published in the prestigious journal Alimentary Pharmacology & Therapeutics (a TOP journal in the 1st area of the Chinese Academy of Sciences).
Doctor Thomas Reiberger: Hotly Debated Issues on the Use of Non-Selective Beta-Blockers (NSBBs) in the Treatment of Cirrhosis

Doctor Thomas Reiberger: Hotly Debated Issues on the Use of Non-Selective Beta-Blockers (NSBBs) in the Treatment of Cirrhosis

2023.12.21
🔍 Exploring the Complexities of Cirrhosis Treatment: Insights from Dr. Thomas Reiberger Welcome to the latest feature from Hepatology Digest, where we delve into the nuanced world of liver health. In our upcoming article, we're excited to present the esteemed Dr. Thomas Reiberger, a leading figure in hepatology, known for his extensive research and clinical expertise. Dr. Reiberger brings a wealth of knowledge to the table, particularly in the controversial use of Non-Selective Beta-Blockers (NSBBs) for treating cirrhosis. Join us as we navigate the complexities of this treatment, examining its benefits, challenges, and the heated debates it sparks in the medical community. Stay tuned for an enlightening journey through the lens of a distinguished expert. 🔗 Stay connected with Hepatology Digest for cutting-edge insights and discussions.
Dr. Lai Wei’s Team at Tsinghua Chang Gung: Latest Developments in the Nationwide “MAFLD Epidemiological Survey Research Project” on Health Check-up

Dr. Lai Wei’s Team at Tsinghua Chang Gung: Latest Developments in the Nationwide “MAFLD Epidemiological Survey Research Project” on Health Check-up

2023.12.21
In 2020, the international expert consensus on metabolic dysfunction-associated fatty liver disease (MAFLD) proposed a new definition, suggesting MAFLD as a more appropriate term to describe liver diseases related to metabolic dysfunction. According to the latest standards, patients with liver fat deposition meet at least one of the following three criteria: overweight or obesity, type 2 diabetes, or the presence of metabolic dysfunction (if their weight is normal). To comprehensively understand the current status of MAFLD in China, promote awareness among medical professionals and patients, and increase the diagnosis rate of the disease, in 2022, the National Health Examination Population "MAFLD Epidemiological Survey Research Project," led by Dr. Lai Wei of Tsinghua University Affiliated Beijing Tsinghua Chang Gung Hospital and co-initiated by the China Liver Health Promotion Center, was successfully launched. The two latest research findings from the project have been included in the 2023 Annual Meeting of the American Association for the Study of Liver Disease (AASLD). Dr. Lai Wei has been invited by the Hepatology Digest to provide a detailed introduction to these two studies, the content of which is shared below.
AASLD Voice of China | Dr. Zhenhuan Cao’s Team: The Impact of Hepatic Steatosis on Antiviral Therapy in Patients with Chronic Hepatitis B

AASLD Voice of China | Dr. Zhenhuan Cao’s Team: The Impact of Hepatic Steatosis on Antiviral Therapy in Patients with Chronic Hepatitis B

2023.12.21
From November 10th to 14th, 2023, the annual highlight in the field of hepatology—the American Association for the Study of Liver Diseases (AASLD) Annual Meeting 2023 was grandly held in Boston, USA. Dr. Zhenhuan Cao from Beijing You'an Hospital, Capital Medical University, as the corresponding author, presented a research abstract at the conference, revealing the influence of hepatic steatosis on the efficacy of antiviral therapy in patients with chronic hepatitis B (CHB). The results suggest that hepatic steatosis has no significant impact on the effectiveness of nucleos(t)ide analogs (NAs) and pegylated interferon (PEG-IFN) treatment [1]. Hepatology Digest reports on this, and the relevant content is shared below.
Dr. Hongfei Zhang’s Team: Latest Stage Data Revealed for China’s “Sprout” Project, Aiding Clinical Cure for Children with Chronic Hepatitis B

Dr. Hongfei Zhang’s Team: Latest Stage Data Revealed for China’s “Sprout” Project, Aiding Clinical Cure for Children with Chronic Hepatitis B

2023.12.21
Chronic hepatitis B is the leading cause of liver disease in Chinese children, posing a serious threat to their health. The "Sprout" project is China's first large-scale real-world study focusing on antiviral treatment for chronic hepatitis B in children. Led by Dr. Hongfei Zhang's team, with Shenzhen Third People's Hospital as the main center, the project is a charitable initiative initiated by the Beijing Chen Jumei Foundation. On November 10, 2023, the first day of the 2023 American Association for the Study of Liver Diseases Annual Meeting (AASLD 2023), Dr. Hongfei Zhang's team from the Chen Jumei Medical Group presented the latest stage data of the "Sprout" project. The team's detailed introduction to the project and its progress is shared below.
AASLD 2023: 17 Must-See Studies

AASLD 2023: 17 Must-See Studies

2023.12.21
From November 10th to 14th, the annualHepatology Digest conference, the American Association for the Study of Liver Diseases (AASLD) 2023 held in Boston, USA. This event gathers the latest academic developments, clinical research findings, and major academic presentations in the field of liver disease. The following is a summary of 17 highly anticipated studies scheduled for presentation at the AASLD 2023 conference.
Headline: AASLD Hot Updates on MASLD from the 2023 Annual Meeting

Headline: AASLD Hot Updates on MASLD from the 2023 Annual Meeting

2023.12.21
On November 7, 2023, at 12:30 PM local time in Boston, the American Association for the Study of Liver Diseases (AASLD) held its sole pre-conference press briefing on Metabolic Associated Fatty Liver Disease (MASLD). Chaired by conference president Professor Norah Terrault, the event featured presentations by Professor Phuc Le of the Cleveland Clinic Lerner College of Medicine, who discussed his team's model predicting the changing prevalence of liver diseases in the U.S. until 2050. Dr. Zobair Younossi, the Global NASH Council Chairman, presented the latest findings on the correlation between food insecurity and MAFLD in American adolescents. Additionally, Dr. Rohit Loomba shared insights into the renaming of Non-Alcoholic Fatty Liver Disease (NAFLD) and the challenges associated with it.
AASLD Voice of China丨Dr. Fengmin Lu: A1762T/G1764A Mutation Promotes HBV Replication, HNF1α Holds Promise as a Novel Therapeutic Target

AASLD Voice of China丨Dr. Fengmin Lu: A1762T/G1764A Mutation Promotes HBV Replication, HNF1α Holds Promise as a Novel Therapeutic Target

2023.12.21
From November 10th to 14th, the annual highlight of hepatology, the American Association for the Study of Liver Diseases (AASLD) 2023, was grandly held in Boston, USA. With over 200 abstracts from Chinese experts and scholars selected for oral presentations or poster sessions, the achievements were commendable. Congratulations to all! Dr. Fengmin Lu's team from Peking University has three contributions to this event (1 oral presentation and 2 posters). Today, we'll share insights from one of the posters presented on the first day, November 10th, revealing the team's academic prowess. The research discovered that the A1762T/G1764A mutation, by affecting the HBV transcriptome, can promote HBV replication (Abstract Number: 1514-C).